Stock comparison
Haemonetics
Haleon
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
HLN
Haleon
Market cap
$41.25B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | HLN | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 54D | HAE |
| Benjamin Graham | 85A | 55C | HAE |
| Philip Fisher | 60C | 49D | HAE |
| Peter Lynch | 54C | 54C | Tie |
| Joel Greenblatt | 31F | 49D | HLN |
| Charlie Munger | 54D | 47D | HAE |
| Terry Smith | 55D | 43D | HAE |
Side-by-side metrics
| Metric | HAE | HLN |
|---|---|---|
| Market cap | $2.98B | $41.25B |
| P/E (TTM) | 24.8x | 28.8x |
| EV/EBIT | 14.1x | 35.6x |
| ROIC (TTM) | 8.37% | 4.13% |
| Gross margin | 55.74% | 61.45% |
| Net margin | 7.29% | 12.59% |
| Revenue CAGR 5y | 7.65% | 3.11% |
| EPS CAGR 5y | 24.62% | 4.66% |
| Debt / Equity | 1.5x | 0.5x |
| Dividend yield | 0.0% | 2.15% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 4.66%+81%
- EV/EBIT14.1xvs 35.6x+60%
- Revenue CAGR 5y7.65%vs 3.11%+59%
- ROIC (TTM)8.37%vs 4.13%+51%
HLN leads on
- Dividend yield2.15%vs 0.0%+100%
- Market cap$41.25Bvs $2.98B+93%
- Debt / Equity0.5xvs 1.5x+66%
- Net margin12.59%vs 7.29%+42%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.